1. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. (February 2022) Authors: Peyrin-Biroulet, Laurent; Hart, Ailsa; Bossuyt, Peter; Long, Millie; Allez, Matthieu; Juillerat, Pascal; Armuzzi, Alessandro; Loftus, Edward V; Ostad-Saffari, Elham; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Lacey, Stuart; Sandborn, William J; Aguilar, Humberto; Ah... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. (January 2022) Authors: Vermeire, Severine; Lakatos, Peter L; Ritter, Timothy; Hanauer, Stephen; Bressler, Brian; Khanna, Reena; Isaacs, Kim; Shah, Saumin; Kadva, Alysha; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Eden, Christopher; Zhang, Wenhui; Feagan, Brian G; Abraham, Philip; Acir Crip... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE. (22nd January 2022) Authors: Loftus, Edward; Pollack, Paul; Hunter, Theresa; Shan, Mingyang; Chan, Lai-Shan; Deckard, Deanilee; Cross, Raymond Journal: Inflammatory bowel diseases Issue: Volume 28(2022)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1. (March 2016) Authors: Sandborn, William; Gasink, Christopher; Blank, Marion; Lang, Yinghua; Johanns, Jewel; Gao, Long-Long; Sands, Bruce; Hanauer, Stephen; Feagan, Brian; Targan, Stephan; Ghosh, Subrata; de Villiers, Wim; Colombel, Jean-Frédéric; Lee, Scott; Desreumaux, Pierre; Loftus, Edward; Vermeire, Severine; Rutg... Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1. (March 2016) Authors: Sandborn, William; Gasink, Christopher; Blank, Marion; Lang, Yinghua; Johanns, Jewel; Gao, Long-Long; Sands, Bruce; Hanauer, Stephen; Feagan, Brian; Targan, Stephan; Ghosh, Subrata; de Villiers, Wim; Colombel, Jean-Frédéric; Lee, Scott; Desreumaux, Pierre; Loftus, Edward; Vermeire, Severine; Rutg... Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials. (19th June 2022) Authors: Laurent, Peyrin-Biroulet; Panaccione, Remo; Gasink, Christopher; Hoops, Timothy; Izanec, James L; Ma, Tony; Nazar, Maciej; Bravata, Ivana; Lahaye, Marjolein; Irving, Peter M; Loftus, Edward; Danese, Silvio; Sands, Bruce Journal: Gut Issue: Volume 71(2022)Supplement 1 Page Start: A17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P-027 YI Cumulative Probability and Outcomes of Anti-tumor Necrosis Factor Use in Patients with Ulcerative Colitis: A Population-Based Study. (March 2016) Authors: Shivashankar, Raina; Harmsen, W. Scott; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P-027 YI Cumulative Probability and Outcomes of Anti-tumor Necrosis Factor Use in Patients with Ulcerative Colitis: A Population-Based Study. (March 2016) Authors: Shivashankar, Raina; Harmsen, W. Scott; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-033 YI Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice. (March 2016) Authors: Chaudrey, Khadija; Lightner, Amy; Singh, Siddharth; Faubion, William; Tremaine, William; Bruining, David; Papadakis, Konstantinos; Kisiel, John; CoelhoPrabhu, Nayantara; Raffals, Laura; Kane, Sunanda; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P-033 YI Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice. (March 2016) Authors: Chaudrey, Khadija; Lightner, Amy; Singh, Siddharth; Faubion, William; Tremaine, William; Bruining, David; Papadakis, Konstantinos; Kisiel, John; CoelhoPrabhu, Nayantara; Raffals, Laura; Kane, Sunanda; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗